<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00045032</url>
  </required_header>
  <id_info>
    <org_study_id>BO16348</org_study_id>
    <secondary_id>BIG-01-01</secondary_id>
    <secondary_id>EU-20216</secondary_id>
    <secondary_id>ROCHE-B016348E</secondary_id>
    <secondary_id>ROCHE-B016348C</secondary_id>
    <secondary_id>EORTC-10011</secondary_id>
    <secondary_id>CAN-NCIC-MA24</secondary_id>
    <secondary_id>IBCSG-28-02</secondary_id>
    <nct_id>NCT00045032</nct_id>
  </id_info>
  <brief_title>Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer</brief_title>
  <acronym>HERA</acronym>
  <official_title>A Randomized Three-Arm, Multicenter Comparison of 1 Year and 2 Years of Herceptin Versus No Herceptin in Women With HER2-Positive Primary Breast Cancer Who Have Completed Adjuvant Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Breast International Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>International Breast Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      The purpose of this trial is to evaluate Herceptin treatment for 1 year and 2 years (versus
      observation/no Herceptin) in women with HER2-overexpressing primary breast cancer who have
      completed (neo-)adjuvant systemic chemotherapy, definitive surgery, and radiotherapy, if
      applicable. Efficacy and safety will be assessed for 10 years from randomization for each
      participant. All participants will continue to be followed for survival until 10 years after
      enrollment of the last participant.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2001</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">March 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Disease-Free Survival (DFS) Events in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up</measure>
    <time_frame>From Baseline until time of event (median of 1 year)</time_frame>
    <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported. The analysis of the Herceptin 1-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed by the Sponsor in 2006 following database cleaning. The analysis of the Herceptin 2-Year Arm against the Observation Arm was performed for an Independent Data Monitoring Committee (IDMC) in 2005 at a time the Sponsor was blinded. Therefore, these data are reported under a separate Outcome Measure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With DFS Events in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up</measure>
    <time_frame>From Baseline until time of event (median of 1 year)</time_frame>
    <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported. The analysis of the Herceptin 2-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed for an IDMC in 2005 at a time the Sponsor was blinded. The analysis of the Herceptin 1-Year Arm against the Observation Arm was performed by the Sponsor in 2006 following database cleaning. Therefore, these data are reported under a separate Outcome Measure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DFS Rate According to Kaplan-Meier Analysis in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up</measure>
    <time_frame>Year 2</time_frame>
    <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95 percent (%) confidence interval (CI) were estimated by Kaplan-Meier analysis based on available data at the time of the 1-year median follow-up analysis. The analysis of the Herceptin 1-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed by the Sponsor in 2006 following database cleaning. The analysis of the Herceptin 2-Year Arm against the Observation Arm was performed for an IDMC in 2005 at a time the Sponsor was blinded. Therefore, these data are reported under a separate Outcome Measure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DFS Rate According to Kaplan-Meier Analysis in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up</measure>
    <time_frame>Year 2</time_frame>
    <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 1-year median follow-up analysis. The analysis of the Herceptin 2-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed for an IDMC in 2005 at a time the Sponsor was blinded. The analysis of the Herceptin 1-Year Arm against the Observation Arm was performed by the Sponsor in 2006 following database cleaning. Therefore, these data are reported under a separate Outcome Measure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With DFS Events Compared to Observation: 8-Year Median Follow-Up</measure>
    <time_frame>From Baseline until time of event (median of 8 years)</time_frame>
    <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DFS Rate at Year 3 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up</measure>
    <time_frame>Year 3</time_frame>
    <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DFS Rate at Year 5 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up</measure>
    <time_frame>Year 5</time_frame>
    <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DFS Rate at Year 7 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up</measure>
    <time_frame>Year 7</time_frame>
    <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DFS Rate at Year 8 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up</measure>
    <time_frame>Year 8</time_frame>
    <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With DFS Events Compared to Observation: 10-Year Maximum Follow-Up</measure>
    <time_frame>From Baseline until time of event (maximum of 10 years)</time_frame>
    <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DFS Rate at Year 3 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up</measure>
    <time_frame>Year 3</time_frame>
    <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DFS Rate at Year 5 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up</measure>
    <time_frame>Year 5</time_frame>
    <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DFS Rate at Year 7 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up</measure>
    <time_frame>Year 7</time_frame>
    <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DFS Rate at Year 8 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up</measure>
    <time_frame>Year 8</time_frame>
    <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DFS Rate at Year 9 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up</measure>
    <time_frame>Year 9</time_frame>
    <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DFS Rate at Year 10 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up</measure>
    <time_frame>Year 10</time_frame>
    <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With DFS Events in 1-Year Versus 2-Year Herceptin: 10-Year Maximum Follow-Up</measure>
    <time_frame>From Baseline until time of event (maximum of 10 years)</time_frame>
    <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DFS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 10-Year Maximum Follow-Up</measure>
    <time_frame>Years 3, 5, 7, 8, 9, 10</time_frame>
    <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Overall Survival (OS) Events in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up</measure>
    <time_frame>From Baseline until time of event (median of 1 year)</time_frame>
    <description>OS events referred to death from any cause. The percentage of participants who died was reported. The analysis of the Herceptin 1-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed by the Sponsor in 2006 following database cleaning. The analysis of the Herceptin 2-Year Arm against the Observation Arm was performed for an IDMC in 2005 at a time the Sponsor was blinded. Therefore, these data are reported under a separate Outcome Measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With OS Events in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up</measure>
    <time_frame>From Baseline until time of event (median of 1 year)</time_frame>
    <description>OS events referred to death from any cause. The percentage of participants who died was reported. The analysis of the Herceptin 2-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed for an IDMC in 2005 at a time the Sponsor was blinded. The analysis of the Herceptin 1-Year Arm against the Observation Arm was performed by the Sponsor in 2006 following database cleaning. Therefore, these data are reported under a separate Outcome Measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS Rate According to Kaplan-Meier Analysis in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up</measure>
    <time_frame>Year 2</time_frame>
    <description>OS events referred to death from any cause. The percentage of participants alive (i.e., the OS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 1-year median follow-up analysis. The analysis of the Herceptin 1-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed by the Sponsor in 2006 following database cleaning. The analysis of the Herceptin 2-Year Arm against the Observation Arm was performed for an IDMC in 2005 at a time the Sponsor was blinded. Therefore, these data are reported under a separate Outcome Measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS Rate According to Kaplan-Meier Analysis in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up</measure>
    <time_frame>Year 2</time_frame>
    <description>OS events referred to death from any cause. The percentage of participants alive (i.e., the OS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 1-year median follow-up analysis. The analysis of the Herceptin 2-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed for an IDMC in 2005 at a time the Sponsor was blinded. The analysis of the Herceptin 1-Year Arm against the Observation Arm was performed by the Sponsor in 2006 following database cleaning. Therefore, these data are reported under a separate Outcome Measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With OS Events Compared to Observation: 8-Year Median Follow-Up</measure>
    <time_frame>From Baseline until time of event (median of 8 years)</time_frame>
    <description>OS events referred to death from any cause. The percentage of participants who died was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up</measure>
    <time_frame>Years 3, 5, 7, 8</time_frame>
    <description>OS events referred to death from any cause. The percentage of participants alive (i.e., the OS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With OS Events Compared to Observation: 11-Year Median Follow-Up</measure>
    <time_frame>From Baseline until time of event (median of 11 years)</time_frame>
    <description>OS events referred to death from any cause. The percentage of participants who died was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS Rate According to Kaplan-Meier Analysis Compared to Observation: 11-Year Median Follow-Up</measure>
    <time_frame>Years 3, 5, 7, 9, 10, 11, 12</time_frame>
    <description>OS events referred to death from any cause. The percentage of participants alive (i.e., the OS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with an 11-year median follow-up for OS events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With OS Events in 1-Year Versus 2-Year Herceptin: 11-Year Median Follow-Up</measure>
    <time_frame>From Baseline until time of event (median of 11 years)</time_frame>
    <description>OS events referred to death from any cause. The percentage of participants who died was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 11-Year Median Follow-Up</measure>
    <time_frame>Years 3, 5, 7, 9, 10, 11, 12</time_frame>
    <description>OS events referred to death from any cause. The percentage of participants alive (i.e., the OS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with an 11-year median follow-up for OS events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Recurrence-Free Survival (RFS) Events Compared to Observation: 8-Year Median Follow-Up</measure>
    <time_frame>From Baseline until time of event (median of 8 years)</time_frame>
    <description>RFS events included local, regional, or distant tumor recurrence. The percentage of participants with at least one RFS event was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RFS Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up</measure>
    <time_frame>Years 3, 5, 7, 8</time_frame>
    <description>RFS events included local, regional, or distant tumor recurrence. The percentage of participants free of RFS events (i.e., the RFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With RFS Events in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up</measure>
    <time_frame>From Baseline until time of event (median of 8 years)</time_frame>
    <description>RFS events included local, regional, or distant tumor recurrence. The percentage of participants with at least one RFS event was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RFS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up</measure>
    <time_frame>Years 3, 5, 7, 8</time_frame>
    <description>RFS events included local, regional, or distant tumor recurrence. The percentage of participants free of RFS events (i.e., the RFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Distant Disease-Free Survival (DDFS) Events Compared to Observation: 8-Year Median Follow-Up</measure>
    <time_frame>From Baseline until time of event (median of 8 years)</time_frame>
    <description>DDFS events included distant tumor recurrence, second primary cancer, or contralateral breast cancer. The percentage of participants with at least one DDFS event was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DDFS Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up</measure>
    <time_frame>Years 3, 5, 7, 8</time_frame>
    <description>DDFS events included distant tumor recurrence, second primary cancer, or contralateral breast cancer. The percentage of participants free of DDFS events (i.e., the DDFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With DDFS Events in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up</measure>
    <time_frame>From Baseline until time of event (median of 8 years)</time_frame>
    <description>DDFS events included distant tumor recurrence, second primary cancer, or contralateral breast cancer. The percentage of participants with at least one DDFS event was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DDFS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up</measure>
    <time_frame>Years 3, 5, 7, 8</time_frame>
    <description>DDFS events included distant tumor recurrence, second primary cancer, or contralateral breast cancer. The percentage of participants free of DDFS events (i.e., the DDFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Tumor Recurrence (TR) Compared to Observation: 8-Year Median Follow-Up</measure>
    <time_frame>From Baseline until time of event (median of 8 years)</time_frame>
    <description>The percentage of participants with TR of the present breast cancer was reported. TR included local, regional, or distant tumor ignoring contralateral breast cancer and second non-breast malignancy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TR-Free Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up</measure>
    <time_frame>Years 3, 5, 7, 8</time_frame>
    <description>The percentage of participants without TR of the present breast cancer (i.e., the TR-free rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis. TR included local, regional, or distant tumor ignoring contralateral breast cancer and second non-breast malignancy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With TR in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up</measure>
    <time_frame>From Baseline until time of event (median of 8 years)</time_frame>
    <description>The percentage of participants with TR of the present breast cancer was reported. TR included local, regional, or distant tumor ignoring contralateral breast cancer and second non-breast malignancy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TR-Free Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up</measure>
    <time_frame>Years 3, 5, 7, 8</time_frame>
    <description>The percentage of participants without TR of the present breast cancer (i.e., the TR-free rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis. TR included local, regional, or distant tumor ignoring contralateral breast cancer and second non-breast malignancy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Distant Tumor Recurrence (DTR) Compared to Observation: 8-Year Median Follow-Up</measure>
    <time_frame>From Baseline until time of event (median of 8 years)</time_frame>
    <description>The percentage of participants with DTR was reported. DTR included distant tumors ignoring local and regional recurrences, contralateral breast cancer, and second non-breast malignancy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DTR-Free Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up</measure>
    <time_frame>Years 3, 5, 7, 8</time_frame>
    <description>The percentage of participants without DTR (i.e., the DTR-free rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis. DTR included distant tumors ignoring local and regional recurrences, contralateral breast cancer, and second non-breast malignancy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With DTR in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up</measure>
    <time_frame>From Baseline until time of event (median of 8 years)</time_frame>
    <description>The percentage of participants with DTR was reported. DTR included distant tumors ignoring local and regional recurrences, contralateral breast cancer, and second non-breast malignancy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DTR-Free Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up</measure>
    <time_frame>Years 3, 5, 7, 8</time_frame>
    <description>The percentage of participants without DTR (i.e., the DTR-free rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis. DTR included distant tumors ignoring local and regional recurrences, contralateral breast cancer, and second non-breast malignancy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Restricted Disease-Free Survival (RDFS) Events in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up</measure>
    <time_frame>From Baseline until time of event (median of 8 years)</time_frame>
    <description>RDFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer, or death from any cause. The percentage of participants with at least one RDFS event was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RDFS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up</measure>
    <time_frame>Years 3, 5, 7, 8</time_frame>
    <description>RDFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer, or death from any cause. The percentage of participants free of RDFS events (i.e., the RDFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Primary Cardiac Endpoint Events Compared to Observation: 10-Year Maximum Follow-Up</measure>
    <time_frame>From Baseline until time of event (maximum up to 10 years)</time_frame>
    <description>Primary cardiac endpoint events included the occurrence of any of the following between randomization and new therapy for recurrent disease: symptomatic New York Heart Association (NYHA) Class III or IV congestive heart failure (CHF) confirmed by a cardiologist with a drop in left ventricular ejection fraction (LVEF) at least 10 percentage points from Baseline and to a value less than (&lt;) 50%, and documentation of definite or probable cardiac death. Definite cardiac death included CHF, myocardial infarction, or primary arrhythmia. Probable cardiac death included unexpected sudden death within 24 hours of a cardiac event (syncope, cardiac arrest, chest pain, infarction, arrhythmia) without documented etiology. The percentage of participants with at least one primary cardiac endpoint event was reported. The 95% CI was calculated by the Pearson-Clopper method for a one-sample binomial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Secondary Cardiac Endpoint Events Compared to Observation: 10-Year Maximum Follow-Up</measure>
    <time_frame>From Baseline until time of event (maximum up to 10 years)</time_frame>
    <description>Secondary cardiac endpoint events included NYHA Class I or II CHF with a drop in LVEF measured by multiple-gated acquisition or electrocardiogram, unless the subsequent assessment of LVEF indicated a return to levels that did not meet the definition of a significant LVEF drop. A significant LVEF drop was defined as an absolute reduction of at least 10 percentage points from Baseline and to a value &lt;50%. The percentage of participants with at least one secondary cardiac endpoint event was reported, excluding those with both a primary and secondary cardiac endpoint event. The 95% CI was calculated by the Pearson-Clopper method for a one-sample binomial.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">5099</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Observation Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants who have completed definitive surgery and systemic adjuvant chemotherapy will be observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin will be provided.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Herceptin 1-Year Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who have completed definitive surgery and systemic adjuvant chemotherapy will receive Herceptin for 1 year or until disease recurrence, whichever occurs first. Participants will be observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Herceptin 2-Year Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who have completed definitive surgery and systemic adjuvant chemotherapy will receive Herceptin for 2 years or until disease recurrence, whichever occurs first. Participants will be observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Herceptin</intervention_name>
    <description>Herceptin will be given as a loading dose of 8 milligrams per kilogram (mg/kg) via intravenous (IV) infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks.</description>
    <arm_group_label>Herceptin 1-Year Arm</arm_group_label>
    <other_name>Trastuzumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Herceptin</intervention_name>
    <description>Herceptin will be given as a loading dose of 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks.</description>
    <arm_group_label>Herceptin 2-Year Arm</arm_group_label>
    <other_name>Trastuzumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-metastatic primary invasive breast cancer overexpressing HER2 (determined by
             immunohistochemistry 3+ or positive fluorescence in situ hybridization test) that has
             been histologically confirmed, adequately excised, axillary node positive or negative,
             and tumor size at least T1c according to Tumor/Node/Metastasis (TNM) staging

          -  Completion of at least 4 cycles of (neo-)adjuvant systemic chemotherapy, definitive
             surgery, and radiotherapy, if applicable

          -  Known hormone receptor status

          -  Baseline left ventricular ejection fraction (LVEF) greater than or equal to (â‰¥) 55
             percent (%)

        Exclusion Criteria:

          -  Prior invasive breast carcinoma

          -  Other malignancies except for curatively treated basal and squamous cell carcinoma of
             the skin or in situ carcinoma of the cervix

          -  Clinical T4 tumors

          -  Cumulative doxorubicin exposure greater than (&gt;) 360 milligrams per meter-squared
             (mg/m^2) or epirubicin &gt;720 mg/m^2 or any prior anthracyclines unrelated to the
             present breast cancer

          -  Peripheral stem cell or bone marrow stem cell support

          -  Prior mediastinal irradiation except for internal mammary node irradiation for the
             present breast cancer

          -  Non-irradiated internal mammary nodes or supraclavicular lymph node involvement

          -  Prior anti-HER2 therapy for any other reason or other prior biologic or immunotherapy
             for breast cancer

          -  Concurrent anti-cancer treatment in another investigational trial

          -  Serious cardiac or pulmonary conditions/illness, or any other conditions that could
             interfere with planned treatment

          -  Poor hematologic, hepatic, or renal function

          -  Pregnancy or lactation

          -  Women of childbearing potential or less than 1 year post-menopause unwilling to use
             adequate contraceptive measures
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martine J. Piccart-Gebhart, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Jules Bordet Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert E. Coleman, MD, FRCP</last_name>
    <role>Study Chair</role>
    <affiliation>Cancer Research Centre at Weston Park Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karen A. Gelmon, MD</last_name>
    <role>Study Chair</role>
    <affiliation>British Columbia Cancer Agency</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathleen I. Pritchard, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Toronto Sunnybrook Regional Cancer Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olivia Pagani, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ospedale Beata Vergine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Aleman de Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1118</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint John of God Hospital</name>
      <address>
        <city>Geelong</city>
        <state>Australian Capital Territory</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toowoomba Hospital</name>
      <address>
        <city>Toowoomba</city>
        <state>Queensland</state>
        <zip>4350</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andrew Love Cancer Centre</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landeskrankenhaus Feldkirch</name>
      <address>
        <city>Feldkirch-Tisis</city>
        <zip>6807</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innsbruck Universitaetsklinik</name>
      <address>
        <city>Innsbruck</city>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landeskrankenhaus Klagenfurt</name>
      <address>
        <city>Klagenfurt</city>
        <zip>9026</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Linz Donau</city>
        <zip>A-4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landeskrankenanstalten - Salzburg</name>
      <address>
        <city>Salzburg</city>
        <zip>A-5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landeskrankenhaus St. Poelten</name>
      <address>
        <city>St. Poelten</city>
        <zip>3100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik fuer Innere Medizin I</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilhelminenspital der Stadt Wien</name>
      <address>
        <city>Vienna</city>
        <zip>A-1160</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LKH Villach</name>
      <address>
        <city>Villach</city>
        <zip>9500</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LKH Voecklabruck</name>
      <address>
        <city>Voecklabruck</city>
        <zip>4840</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A. oe. Krankenhaus Wiener Neustadt</name>
      <address>
        <city>Wiener Neustadt</city>
        <zip>A-2700</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Netwerk Antwerpen Middelheim</name>
      <address>
        <city>Antwerp</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reseau Hospitalier De Medecine Sociale</name>
      <address>
        <city>Baudour</city>
        <zip>7331</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Universitaire Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis der Vrije Universiteit Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>B-1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Notre Dame - Reine Fabiola</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cazk Groeninghe - Campus St-Niklaas</name>
      <address>
        <city>Kortrijk</city>
        <zip>B-8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Tivoli</name>
      <address>
        <city>La Louviere</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Saint-Joseph</name>
      <address>
        <city>Liege</city>
        <zip>B 4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Liege - Domaine Universitaire du Sart Tilman</name>
      <address>
        <city>Liege</city>
        <zip>B-4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Sainte Elisabeth</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Serruys Ziekenhuis</name>
      <address>
        <city>Oostende</city>
        <zip>8400</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Peltzer-La Tourelle</name>
      <address>
        <city>Verviers</city>
        <zip>B-4800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Porto Alegre Hospital</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>90035-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sao Lucas da PUCRS</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Rita</name>
      <address>
        <city>Porto Alegre</city>
        <zip>91330-490</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cancer</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20560-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculdade De Medicina Do ABC</name>
      <address>
        <city>Santo Andre</city>
        <zip>09060-650</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre - Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency - Centre for the Southern Interior</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fraser Valley Cancer Centre at British Columbia Cancer Agency</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency - Vancouver Island Cancer Centre</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 6V5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2H 2A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital of Barrie</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6M2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Margaret and Charles Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trillium Health Centre - Mississauga Site</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5B 1B8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Algoma Regional Cancer Program at Sault Area Hospital</name>
      <address>
        <city>Sault Sainte Marie</city>
        <state>Ontario</state>
        <zip>P6A 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu Health Sciences Hospital - Niagara</name>
      <address>
        <city>St. Catharines</city>
        <state>Ontario</state>
        <zip>L2R 5K3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto East General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4C 3E7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital - Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Windsor Regional Cancer Centre at Windsor Regional Hospital</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 2X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince Edward Island Cancer Centre at Queen Elizabeth Hospital</name>
      <address>
        <city>Charlottetown</city>
        <state>Prince Edward Island</state>
        <zip>C1A 8T5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital du Saint-Sacrement, Quebec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allan Blair Cancer Centre at Pasqua Hospital</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saskatoon Cancer Centre at the University of Saskatchewan</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Arturo Lopez Perez</name>
      <address>
        <city>Santiago</city>
        <zip>29</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Borja Arriaran</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Dr. Sotero Del Rio</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Militar</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional Del Cancer</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tuen Mun Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tongji Medical University</name>
      <address>
        <city>Wuhan</city>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional De Cancerologia</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Split</name>
      <address>
        <city>Split</city>
        <zip>21000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centralsygehus I Esbjerg</name>
      <address>
        <city>Esbjerg</city>
        <zip>6700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herning Central Hospital</name>
      <address>
        <city>Herning</city>
        <zip>7400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillerod Hospital</name>
      <address>
        <city>Hillerod</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centralsygehuset I Naestved</name>
      <address>
        <city>Naestved</city>
        <zip>4700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sonderborg Sygehus</name>
      <address>
        <city>Sonderborg</city>
        <zip>6400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospital Regional Universitaire de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Clinique Claude Bernard</name>
      <address>
        <city>Metz</city>
        <zip>57072</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite - Campus Charite Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>D-10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelisches Bethesda Krankenhaus GmbH</name>
      <address>
        <city>Essen</city>
        <zip>D-45355</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>D-79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin Luther Universitaet</name>
      <address>
        <city>Halle</city>
        <zip>D-06097</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henriettenstiftung Krankenhaus</name>
      <address>
        <city>Hanover</city>
        <zip>D-30559</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaets-Hautklinik Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>D-69115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincentius-Kliniken</name>
      <address>
        <city>Karlsruhe</city>
        <zip>D-76137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Schleswig-Holstein - Kiel Campus</name>
      <address>
        <city>Kiel</city>
        <zip>D-24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kreiskrankenhaus Leonberg - Frauenklinik</name>
      <address>
        <city>Leonberg</city>
        <zip>D-71229</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinkum Magdeburg der Otto-von-Guericke-Universitaet Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>D-39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frauenklinik Vom Roten Kreuz</name>
      <address>
        <city>Munich</city>
        <zip>80637</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts Der Isar - Technische Universitaet Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>D-81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frauenklinik - Universitaetsklinikum Rostock am Klinikum Sudstadt</name>
      <address>
        <city>Rostock</city>
        <zip>D-18059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaet Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>D-89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Horst-Schmidt-Kliniken</name>
      <address>
        <city>Wiesbaden</city>
        <zip>D-65199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Crete School of Medicine</name>
      <address>
        <city>Heraklion</city>
        <state>Crete</state>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evaggelismos Hospital</name>
      <address>
        <city>Athens</city>
        <zip>10676</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico</name>
      <address>
        <city>Guatemala City</city>
        <zip>01010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Roosevelt</name>
      <address>
        <city>Guatemala City</city>
        <zip>01010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Shatin, New Territories</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University</name>
      <address>
        <city>Budapest</city>
        <zip>1082</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Oncology</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fovarosi Onkormanyzat Szent Margit Korhaz, Okologia</name>
      <address>
        <city>Budapest</city>
        <zip>H-1032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cork University Hospital</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sieff Hospital</name>
      <address>
        <city>Safed</city>
        <zip>13110</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Lazzaro</name>
      <address>
        <city>Alba</city>
        <zip>12051</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Presenti Fenaroli</name>
      <address>
        <city>Alzano-Lombardo</city>
        <zip>24022</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro di Riferimento Oncologico - Aviano</name>
      <address>
        <city>Aviano</city>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti di Bergamo</name>
      <address>
        <city>Bergamo</city>
        <zip>24100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale degli Infermi - ASL 12</name>
      <address>
        <city>Biella</city>
        <zip>13900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Bellaria</name>
      <address>
        <city>Bologna</city>
        <zip>I-40139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Oncologico A. Businco</name>
      <address>
        <city>Cagliari</city>
        <zip>09100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale B. Ramazzini</name>
      <address>
        <city>Carpi</city>
        <zip>41012</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Valduce</name>
      <address>
        <city>Como</city>
        <zip>22100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Croce</name>
      <address>
        <city>Cuneo</city>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita Degli Studi Di Florence</name>
      <address>
        <city>Firenze (Florence)</city>
        <zip>50121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Careggi</name>
      <address>
        <city>Florence</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morgagni-Pierantoni Ospedale</name>
      <address>
        <city>Forli</city>
        <zip>47100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale per la Ricerca sul Cancro</name>
      <address>
        <city>Genoa</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale A. Manzoni</name>
      <address>
        <city>Lecco</city>
        <zip>23900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero</name>
      <address>
        <city>Livorno</city>
        <zip>57100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carlo Poma Hospital</name>
      <address>
        <city>Mantova</city>
        <zip>46100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>European Institute of Oncology</name>
      <address>
        <city>Milan</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Niguarda Ca'Granda</name>
      <address>
        <city>Milan</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Modena Hospital and Reggio Emilia School of Medicine</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Di Parma</name>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I.R.C.C.S. Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Monteluce</name>
      <address>
        <city>Perugia</city>
        <zip>06122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Filippo Neri</name>
      <address>
        <city>Rome</city>
        <zip>00135</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Sant' Eugenio</name>
      <address>
        <city>Rome</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile ASL 1</name>
      <address>
        <city>Sassari</city>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primario U.O. di Oncologia Medica</name>
      <address>
        <city>Trento</city>
        <zip>38100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Ostetrico Ginecologica Sant Anna</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita di Torino</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokai University School Of Medicine</name>
      <address>
        <city>Kanagawa</city>
        <zip>259-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Metropolitan - Komagome Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei Cancer Center at Yonsei University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Maastricht</name>
      <address>
        <city>Maastricht</city>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maasland Hospital</name>
      <address>
        <city>Sittard</city>
        <zip>6131 BK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonessenhuis Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3508 TG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Gdansk</name>
      <address>
        <city>Gdansk</city>
        <zip>80-211</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncologic Center</name>
      <address>
        <city>Gliwice</city>
        <zip>44-101</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University</name>
      <address>
        <city>Poznan</city>
        <zip>61-878</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology</name>
      <address>
        <city>Warsaw</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Portugues de Oncologia, Centro Regional de Coimbra</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospitais da Universidade de Coimbra (HUC)</name>
      <address>
        <city>Coimbra</city>
        <zip>3000</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maternidade Byssaia Barreto</name>
      <address>
        <city>Coimbra</city>
        <zip>3000</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Distrital De Faro</name>
      <address>
        <city>Faro</city>
        <zip>8000</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Santa Maria</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Portugues de Oncologia de Francisco Gentil - Centro Regional de Oncologia de Lisboa, S.A.</name>
      <address>
        <city>Lisbon</city>
        <zip>1099-023 Codex</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow Oncology Hospital</name>
      <address>
        <city>Moscow</city>
        <zip>107005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P.A. Hertzen Research Oncology Institute</name>
      <address>
        <city>Moscow</city>
        <zip>125284</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Singapore International Medical Centre</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groote Schuur Hospital</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parklands Hospital</name>
      <address>
        <city>Durban</city>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandton Oncology Centre</name>
      <address>
        <city>Johannesburg</city>
        <zip>2121</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Centre of Rosebank</name>
      <address>
        <city>Johannesburg</city>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pretoria - East Hospital</name>
      <address>
        <city>Lynnwood</city>
        <zip>0081</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital De La Ribera</name>
      <address>
        <city>Alzira</city>
        <zip>46600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Cecilio de Granada</name>
      <address>
        <city>Granada</city>
        <zip>18003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario De Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <zip>19002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Juan Ramon Jimenez</name>
      <address>
        <city>Huelva</city>
        <zip>21005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Cuidad de Jaen</name>
      <address>
        <city>Jaen</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico De Galicia Jose Antonio Quirogay Pineyro</name>
      <address>
        <city>La Coruna</city>
        <zip>15009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Canarias</name>
      <address>
        <city>La Laguna</city>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Gran Canaria Dr. Negrin</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <zip>35020</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Insular de Gran Canaria</name>
      <address>
        <city>Las Palmas</city>
        <zip>G.C.</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Santa Maria</name>
      <address>
        <city>Orense</city>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Pontevedra</name>
      <address>
        <city>Pontevedra</city>
        <zip>36001</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consorci Hospitalari del Parc Tauli</name>
      <address>
        <city>Sabadell</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Nuestra Senora de la Candelaria</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <zip>38010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universidad Virgen Del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>E- 41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen Del La Salud</name>
      <address>
        <city>Toledo</city>
        <zip>45004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Xeral de Vigo</name>
      <address>
        <city>Vigo Pontevedra</city>
        <zip>36204</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>59009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Linkoping</name>
      <address>
        <city>Linkoping</city>
        <zip>S-581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Malmoe</name>
      <address>
        <city>Malmo</city>
        <zip>20502</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital - Molndal at Gothenburg University</name>
      <address>
        <city>Molndal</city>
        <zip>S-43180</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital - Huddinge</name>
      <address>
        <city>Stockholm</city>
        <zip>S-171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Umea Universitet</name>
      <address>
        <city>Umea</city>
        <zip>SE-901 87</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital-Basel</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitaeler Chur AG</name>
      <address>
        <city>Chur</city>
        <zip>CH-7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Beata Vergine</name>
      <address>
        <city>Mendrisio</city>
        <zip>CH-6850</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital - St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitaetsSpital Zuerich</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chulalongkorn University Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ramathibodi Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bradford Hospitals NHS Trust</name>
      <address>
        <city>Bradford</city>
        <state>England</state>
        <zip>BD9 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Broomfield Hospital</name>
      <address>
        <city>Chelmsford, Essex</city>
        <state>England</state>
        <zip>CM1 7ET</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Margaret's Hospital</name>
      <address>
        <city>Epping Essex</city>
        <state>England</state>
        <zip>CM16 6TN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diana Princess of Wales Hospital</name>
      <address>
        <city>Grimsby</city>
        <state>England</state>
        <zip>DN33 2BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huddersfield Royal Infirmary</name>
      <address>
        <city>Huddersfield, West Yorks</city>
        <state>England</state>
        <zip>HD3 3EA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Royal Hospital</name>
      <address>
        <city>Hull</city>
        <state>England</state>
        <zip>HU8 9HE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cookridge Hospital at Leeds Teaching Hospital NHS Trust</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS16 6QB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College of Medicine</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Cook University Hospital</name>
      <address>
        <city>Middlesbrough</city>
        <state>England</state>
        <zip>TS4 3BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Centre for Cancer Treatment at Newcastle General Hospital</name>
      <address>
        <city>Newcastle-Upon-Tyne</city>
        <state>England</state>
        <zip>NE4 6BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Research Centre at Weston Park Hospital</name>
      <address>
        <city>Sheffield</city>
        <state>England</state>
        <zip>S1O 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Airedale General Hospital</name>
      <address>
        <city>West Yorkshire</city>
        <state>England</state>
        <zip>BD20 6TD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southend NHS Trust Hospital</name>
      <address>
        <city>Westcliff-On-Sea</city>
        <state>England</state>
        <zip>SS0 0RY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>China</country>
    <country>Colombia</country>
    <country>Croatia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Guatemala</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Jahanzeb M. Adjuvant trastuzumab therapy for HER2-positive breast cancer. Clin Breast Cancer. 2008 Aug;8(4):324-33. doi: 10.3816/CBC.2008.n.037. Review.</citation>
    <PMID>18757259</PMID>
  </reference>
  <reference>
    <citation>Shiroiwa T, Fukuda T, Shimozuma K, Ohashi Y, Tsutani K. The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data. Breast Cancer Res Treat. 2008 Jun;109(3):559-66. Epub 2007 Jul 28.</citation>
    <PMID>17661170</PMID>
  </reference>
  <results_reference>
    <citation>Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch C, Cameron D, Mano M, Pedrini JL, Veronesi A, Mendiola C, Pluzanska A, Semiglazov V, Vrdoljak E, Eckart MJ, Shen Z, Skiadopoulos G, Procter M, Pritchard KI, Piccart-Gebhart MJ, Bell R; Herceptin Adjuvant (HERA) Trial Study Team. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011 Mar;12(3):236-44. doi: 10.1016/S1470-2045(11)70033-X. Epub 2011 Feb 25.</citation>
    <PMID>21354370</PMID>
  </results_reference>
  <results_reference>
    <citation>Procter M, Suter TM, de Azambuja E, Dafni U, van Dooren V, Muehlbauer S, Climent MA, Rechberger E, Liu WT, Toi M, Coombes RC, Dodwell D, Pagani O, Madrid J, Hall M, Chen SC, Focan C, Muschol M, van Veldhuisen DJ, Piccart-Gebhart MJ. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol. 2010 Jul 20;28(21):3422-8. doi: 10.1200/JCO.2009.26.0463. Epub 2010 Jun 7.</citation>
    <PMID>20530280</PMID>
  </results_reference>
  <results_reference>
    <citation>Dowsett M, Procter M, McCaskill-Stevens W, de Azambuja E, Dafni U, Rueschoff J, Jordan B, Dolci S, Abramovitz M, Stoss O, Viale G, Gelber RD, Piccart-Gebhart M, Leyland-Jones B. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. J Clin Oncol. 2009 Jun 20;27(18):2962-9. doi: 10.1200/JCO.2008.19.7939. Epub 2009 Apr 13.</citation>
    <PMID>19364966</PMID>
  </results_reference>
  <results_reference>
    <citation>Untch M, Gelber RD, Jackisch C, Procter M, Baselga J, Bell R, Cameron D, Bari M, Smith I, Leyland-Jones B, de Azambuja E, Wermuth P, Khasanov R, Feng-Yi F, Constantin C, Mayordomo JI, Su CH, Yu SY, Lluch A, Senkus-Konefka E, Price C, Haslbauer F, Suarez Sahui T, Srimuninnimit V, Colleoni M, Coates AS, Piccart-Gebhart MJ, Goldhirsch A; HERA Study Team. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol. 2008 Jun;19(6):1090-6. doi: 10.1093/annonc/mdn005. Epub 2008 Feb 21.</citation>
    <PMID>18296421</PMID>
  </results_reference>
  <results_reference>
    <citation>McCaskill-Stevens W, Procter M, Goodbrand J, et al.: Disease-free survival according to local immunohistochemistry for HER2 and central fluorescence in situ hydridization for patients treated with adjuvant chemotherapy with and without trastuzumab in the HERA (BIG 01-01) trial. [Abstract] Breast Cancer Res Treat 106 (1): A-71, S18, 2007.</citation>
  </results_reference>
  <results_reference>
    <citation>Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, SÃ¡nchez Rovira P, Piccart-Gebhart MJ; HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007 Jan 6;369(9555):29-36.</citation>
    <PMID>17208639</PMID>
  </results_reference>
  <results_reference>
    <citation>Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, Perren T, Passalacqua R, Bighin C, Klijn JG, Ageev FT, Hitre E, Groetz J, Iwata H, Knap M, Gnant M, Muehlbauer S, Spence A, Gelber RD, Piccart-Gebhart MJ. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol. 2007 Sep 1;25(25):3859-65. Epub 2007 Jul 23.</citation>
    <PMID>17646669</PMID>
  </results_reference>
  <results_reference>
    <citation>Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, LÃ¡ng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, RÃ¼schoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005 Oct 20;353(16):1659-72.</citation>
    <PMID>16236737</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <results_first_submitted>October 19, 2016</results_first_submitted>
  <results_first_submitted_qc>March 17, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 27, 2017</results_first_posted>
  <last_update_submitted>March 17, 2017</last_update_submitted>
  <last_update_submitted_qc>March 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>After the release of initial study results, participants in the Observation Arm without disease recurrence were given the opportunity to cross over to receive 1 or 2 years of adjuvant Herceptin. Efficacy analyses were still performed according to original randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Observation Arm</title>
          <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin was provided.</description>
        </group>
        <group group_id="P2">
          <title>Herceptin 1-Year Arm</title>
          <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 milligrams per kilogram (mg/kg) via intravenous (IV) infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
        </group>
        <group group_id="P3">
          <title>Herceptin 2-Year Arm</title>
          <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1697">Included all participants with available signed Informed Consent Form.</participants>
                <participants group_id="P2" count="1702">Included all participants with available signed Informed Consent Form.</participants>
                <participants group_id="P3" count="1700">Included all participants with available signed Informed Consent Form.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Crossover to Adjuvant Herceptin</title>
              <participants_list>
                <participants group_id="P1" count="888"/>
                <participants group_id="P2" count="0">This milestone is not applicable to participants who were already randomized to Herceptin.</participants>
                <participants group_id="P3" count="0">This milestone is not applicable to participants who were already randomized to Herceptin.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="834"/>
                <participants group_id="P2" count="994"/>
                <participants group_id="P3" count="974"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="863"/>
                <participants group_id="P2" count="708"/>
                <participants group_id="P3" count="726"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event/Intercurrent Illness</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient Therapeutic Response</title>
              <participants_list>
                <participants group_id="P1" count="542"/>
                <participants group_id="P2" count="437"/>
                <participants group_id="P3" count="445"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Violation of Selection Criteria at Entry</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused/Did Not Cooperate/Withdrew</title>
              <participants_list>
                <participants group_id="P1" count="142"/>
                <participants group_id="P2" count="93"/>
                <participants group_id="P3" count="84"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failure to Return</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="62"/>
                <participants group_id="P3" count="61"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="84"/>
                <participants group_id="P3" count="105"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set (FAS) Population: All enrolled/randomized participants who had an available signed Informed Consent Form.</population>
      <group_list>
        <group group_id="B1">
          <title>Observation Arm</title>
          <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin was provided.</description>
        </group>
        <group group_id="B2">
          <title>Herceptin 1-Year Arm</title>
          <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
        </group>
        <group group_id="B3">
          <title>Herceptin 2-Year Arm</title>
          <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1697"/>
            <count group_id="B2" value="1702"/>
            <count group_id="B3" value="1700"/>
            <count group_id="B4" value="5099"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.2" spread="10.08"/>
                    <measurement group_id="B2" value="49.0" spread="10.06"/>
                    <measurement group_id="B3" value="49.2" spread="10.09"/>
                    <measurement group_id="B4" value="49.1" spread="10.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1697"/>
                    <measurement group_id="B2" value="1702"/>
                    <measurement group_id="B3" value="1700"/>
                    <measurement group_id="B4" value="5099"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Disease-Free Survival (DFS) Events in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up</title>
        <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported. The analysis of the Herceptin 1-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed by the Sponsor in 2006 following database cleaning. The analysis of the Herceptin 2-Year Arm against the Observation Arm was performed for an Independent Data Monitoring Committee (IDMC) in 2005 at a time the Sponsor was blinded. Therefore, these data are reported under a separate Outcome Measure.</description>
        <time_frame>From Baseline until time of event (median of 1 year)</time_frame>
        <population>FAS Population. The &quot;Number of Participants Analyzed&quot; reflects the number with data for the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Observation Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin was provided.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Disease-Free Survival (DFS) Events in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up</title>
          <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported. The analysis of the Herceptin 1-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed by the Sponsor in 2006 following database cleaning. The analysis of the Herceptin 2-Year Arm against the Observation Arm was performed for an Independent Data Monitoring Committee (IDMC) in 2005 at a time the Sponsor was blinded. Therefore, these data are reported under a separate Outcome Measure.</description>
          <population>FAS Population. The &quot;Number of Participants Analyzed&quot; reflects the number with data for the endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1693"/>
                <count group_id="O2" value="1693"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9"/>
                    <measurement group_id="O2" value="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.44</ci_lower_limit>
            <ci_upper_limit>0.67</ci_upper_limit>
            <estimate_desc>HR for Herceptin 1-Year Arm versus Observation Arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With DFS Events in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up</title>
        <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported. The analysis of the Herceptin 2-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed for an IDMC in 2005 at a time the Sponsor was blinded. The analysis of the Herceptin 1-Year Arm against the Observation Arm was performed by the Sponsor in 2006 following database cleaning. Therefore, these data are reported under a separate Outcome Measure.</description>
        <time_frame>From Baseline until time of event (median of 1 year)</time_frame>
        <population>FAS Population. The &quot;Number of Participants Analyzed&quot; reflects the number with data for the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Observation Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin was provided.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With DFS Events in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up</title>
          <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported. The analysis of the Herceptin 2-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed for an IDMC in 2005 at a time the Sponsor was blinded. The analysis of the Herceptin 1-Year Arm against the Observation Arm was performed by the Sponsor in 2006 following database cleaning. Therefore, these data are reported under a separate Outcome Measure.</description>
          <population>FAS Population. The &quot;Number of Participants Analyzed&quot; reflects the number with data for the endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1693"/>
                <count group_id="O2" value="1694"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0"/>
                    <measurement group_id="O2" value="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.34</ci_lower_limit>
            <ci_upper_limit>0.53</ci_upper_limit>
            <estimate_desc>HR for Herceptin 2-Year Arm versus Observation Arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>DFS Rate According to Kaplan-Meier Analysis in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up</title>
        <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95 percent (%) confidence interval (CI) were estimated by Kaplan-Meier analysis based on available data at the time of the 1-year median follow-up analysis. The analysis of the Herceptin 1-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed by the Sponsor in 2006 following database cleaning. The analysis of the Herceptin 2-Year Arm against the Observation Arm was performed for an IDMC in 2005 at a time the Sponsor was blinded. Therefore, these data are reported under a separate Outcome Measure.</description>
        <time_frame>Year 2</time_frame>
        <population>FAS Population. The &quot;Number of Participants Analyzed&quot; reflects the number with data for the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Observation Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin was provided.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>DFS Rate According to Kaplan-Meier Analysis in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up</title>
          <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95 percent (%) confidence interval (CI) were estimated by Kaplan-Meier analysis based on available data at the time of the 1-year median follow-up analysis. The analysis of the Herceptin 1-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed by the Sponsor in 2006 following database cleaning. The analysis of the Herceptin 2-Year Arm against the Observation Arm was performed for an IDMC in 2005 at a time the Sponsor was blinded. Therefore, these data are reported under a separate Outcome Measure.</description>
          <population>FAS Population. The &quot;Number of Participants Analyzed&quot; reflects the number with data for the endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1693"/>
                <count group_id="O2" value="1693"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.18" lower_limit="75" upper_limit="81"/>
                    <measurement group_id="O2" value="85.80" lower_limit="83" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>DFS Rate According to Kaplan-Meier Analysis in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up</title>
        <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 1-year median follow-up analysis. The analysis of the Herceptin 2-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed for an IDMC in 2005 at a time the Sponsor was blinded. The analysis of the Herceptin 1-Year Arm against the Observation Arm was performed by the Sponsor in 2006 following database cleaning. Therefore, these data are reported under a separate Outcome Measure.</description>
        <time_frame>Year 2</time_frame>
        <population>FAS Population. The &quot;Number of Participants Analyzed&quot; reflects the number with data for the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Observation Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin was provided.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>DFS Rate According to Kaplan-Meier Analysis in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up</title>
          <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 1-year median follow-up analysis. The analysis of the Herceptin 2-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed for an IDMC in 2005 at a time the Sponsor was blinded. The analysis of the Herceptin 1-Year Arm against the Observation Arm was performed by the Sponsor in 2006 following database cleaning. Therefore, these data are reported under a separate Outcome Measure.</description>
          <population>FAS Population. The &quot;Number of Participants Analyzed&quot; reflects the number with data for the endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1693"/>
                <count group_id="O2" value="1694"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.60" lower_limit="70" upper_limit="77"/>
                    <measurement group_id="O2" value="87.50" lower_limit="85" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With DFS Events Compared to Observation: 8-Year Median Follow-Up</title>
        <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported.</description>
        <time_frame>From Baseline until time of event (median of 8 years)</time_frame>
        <population>FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>Observation Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin was provided.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
          <group group_id="O3">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With DFS Events Compared to Observation: 8-Year Median Follow-Up</title>
          <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported.</description>
          <population>FAS Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1697"/>
                <count group_id="O2" value="1702"/>
                <count group_id="O3" value="1700"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.6"/>
                    <measurement group_id="O2" value="27.7"/>
                    <measurement group_id="O3" value="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>0.86</ci_upper_limit>
            <estimate_desc>HR for Herceptin 1-Year Arm versus Observation Arm.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
            <estimate_desc>HR for Herceptin 2-Year Arm versus Observation Arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>DFS Rate at Year 3 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up</title>
        <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.</description>
        <time_frame>Year 3</time_frame>
        <population>FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>Observation Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin was provided.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
          <group group_id="O3">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>DFS Rate at Year 3 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up</title>
          <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.</description>
          <population>FAS Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1697"/>
                <count group_id="O2" value="1702"/>
                <count group_id="O3" value="1700"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.2" lower_limit="73.1" upper_limit="77.3"/>
                    <measurement group_id="O2" value="81.3" lower_limit="79.4" upper_limit="83.2"/>
                    <measurement group_id="O3" value="83.5" lower_limit="81.7" upper_limit="85.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>DFS Rate at Year 5 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up</title>
        <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.</description>
        <time_frame>Year 5</time_frame>
        <population>FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>Observation Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin was provided.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
          <group group_id="O3">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>DFS Rate at Year 5 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up</title>
          <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.</description>
          <population>FAS Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1697"/>
                <count group_id="O2" value="1702"/>
                <count group_id="O3" value="1700"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.0" lower_limit="67.8" upper_limit="72.3"/>
                    <measurement group_id="O2" value="75.9" lower_limit="73.8" upper_limit="78.0"/>
                    <measurement group_id="O3" value="76.5" lower_limit="74.4" upper_limit="78.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>DFS Rate at Year 7 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up</title>
        <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.</description>
        <time_frame>Year 7</time_frame>
        <population>FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>Observation Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin was provided.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
          <group group_id="O3">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>DFS Rate at Year 7 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up</title>
          <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.</description>
          <population>FAS Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1697"/>
                <count group_id="O2" value="1702"/>
                <count group_id="O3" value="1700"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.0" lower_limit="63.6" upper_limit="68.3"/>
                    <measurement group_id="O2" value="72.4" lower_limit="70.2" upper_limit="74.6"/>
                    <measurement group_id="O3" value="72.5" lower_limit="70.4" upper_limit="74.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>DFS Rate at Year 8 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up</title>
        <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.</description>
        <time_frame>Year 8</time_frame>
        <population>FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>Observation Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin was provided.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
          <group group_id="O3">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>DFS Rate at Year 8 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up</title>
          <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.</description>
          <population>FAS Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1697"/>
                <count group_id="O2" value="1702"/>
                <count group_id="O3" value="1700"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.8" lower_limit="62.4" upper_limit="67.2"/>
                    <measurement group_id="O2" value="71.2" lower_limit="69.0" upper_limit="73.4"/>
                    <measurement group_id="O3" value="71.0" lower_limit="68.7" upper_limit="73.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With DFS Events Compared to Observation: 10-Year Maximum Follow-Up</title>
        <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported.</description>
        <time_frame>From Baseline until time of event (maximum of 10 years)</time_frame>
        <population>FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>Observation Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin was provided.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
          <group group_id="O3">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With DFS Events Compared to Observation: 10-Year Maximum Follow-Up</title>
          <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported.</description>
          <population>FAS Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1697"/>
                <count group_id="O2" value="1702"/>
                <count group_id="O3" value="1700"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.8"/>
                    <measurement group_id="O2" value="29.7"/>
                    <measurement group_id="O3" value="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>0.86</ci_upper_limit>
            <estimate_desc>HR for Herceptin 1-Year Arm versus Observation Arm.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>0.87</ci_upper_limit>
            <estimate_desc>HR for Herceptin 2-Year Arm versus Observation Arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>DFS Rate at Year 3 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up</title>
        <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.</description>
        <time_frame>Year 3</time_frame>
        <population>FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>Observation Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin was provided.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
          <group group_id="O3">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>DFS Rate at Year 3 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up</title>
          <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.</description>
          <population>FAS Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1697"/>
                <count group_id="O2" value="1702"/>
                <count group_id="O3" value="1700"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.2" lower_limit="73.1" upper_limit="77.3"/>
                    <measurement group_id="O2" value="81.3" lower_limit="79.4" upper_limit="83.2"/>
                    <measurement group_id="O3" value="83.4" lower_limit="81.6" upper_limit="85.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>DFS Rate at Year 5 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up</title>
        <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.</description>
        <time_frame>Year 5</time_frame>
        <population>FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>Observation Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin was provided.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
          <group group_id="O3">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>DFS Rate at Year 5 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up</title>
          <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.</description>
          <population>FAS Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1697"/>
                <count group_id="O2" value="1702"/>
                <count group_id="O3" value="1700"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.0" lower_limit="67.8" upper_limit="72.2"/>
                    <measurement group_id="O2" value="75.9" lower_limit="73.8" upper_limit="78.0"/>
                    <measurement group_id="O3" value="76.4" lower_limit="74.4" upper_limit="78.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>DFS Rate at Year 7 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up</title>
        <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.</description>
        <time_frame>Year 7</time_frame>
        <population>FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>Observation Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin was provided.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
          <group group_id="O3">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>DFS Rate at Year 7 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up</title>
          <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.</description>
          <population>FAS Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1697"/>
                <count group_id="O2" value="1702"/>
                <count group_id="O3" value="1700"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.8" lower_limit="63.5" upper_limit="68.2"/>
                    <measurement group_id="O2" value="72.4" lower_limit="70.2" upper_limit="74.5"/>
                    <measurement group_id="O3" value="72.5" lower_limit="70.3" upper_limit="74.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>DFS Rate at Year 8 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up</title>
        <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.</description>
        <time_frame>Year 8</time_frame>
        <population>FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>Observation Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin was provided.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
          <group group_id="O3">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>DFS Rate at Year 8 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up</title>
          <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.</description>
          <population>FAS Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1697"/>
                <count group_id="O2" value="1702"/>
                <count group_id="O3" value="1700"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.7" lower_limit="62.3" upper_limit="67.0"/>
                    <measurement group_id="O2" value="71.2" lower_limit="69.0" upper_limit="73.4"/>
                    <measurement group_id="O3" value="70.7" lower_limit="68.5" upper_limit="72.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>DFS Rate at Year 9 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up</title>
        <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.</description>
        <time_frame>Year 9</time_frame>
        <population>FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>Observation Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin was provided.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
          <group group_id="O3">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>DFS Rate at Year 9 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up</title>
          <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.</description>
          <population>FAS Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1697"/>
                <count group_id="O2" value="1702"/>
                <count group_id="O3" value="1700"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.5" lower_limit="61.2" upper_limit="65.9"/>
                    <measurement group_id="O2" value="70.3" lower_limit="68.1" upper_limit="72.6"/>
                    <measurement group_id="O3" value="69.2" lower_limit="67.0" upper_limit="71.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>DFS Rate at Year 10 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up</title>
        <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.</description>
        <time_frame>Year 10</time_frame>
        <population>FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>Observation Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin was provided.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
          <group group_id="O3">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>DFS Rate at Year 10 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up</title>
          <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.</description>
          <population>FAS Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1697"/>
                <count group_id="O2" value="1702"/>
                <count group_id="O3" value="1700"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5" lower_limit="60.1" upper_limit="64.8"/>
                    <measurement group_id="O2" value="69.3" lower_limit="67.0" upper_limit="71.5"/>
                    <measurement group_id="O3" value="68.5" lower_limit="66.2" upper_limit="70.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With DFS Events in 1-Year Versus 2-Year Herceptin: 10-Year Maximum Follow-Up</title>
        <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported.</description>
        <time_frame>From Baseline until time of event (maximum of 10 years)</time_frame>
        <population>FAS Population 1-Year Herceptin Versus 2-Year Herceptin (1Y2Y): Participants without a DFS event and still under follow-up at the pre-defined landmark of 366 days after randomization, analyzed when intent-to-treat principle was applied for comparison of 1 year versus 2 years of Herceptin.</population>
        <group_list>
          <group group_id="O1">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With DFS Events in 1-Year Versus 2-Year Herceptin: 10-Year Maximum Follow-Up</title>
          <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported.</description>
          <population>FAS Population 1-Year Herceptin Versus 2-Year Herceptin (1Y2Y): Participants without a DFS event and still under follow-up at the pre-defined landmark of 366 days after randomization, analyzed when intent-to-treat principle was applied for comparison of 1 year versus 2 years of Herceptin.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1552"/>
                <count group_id="O2" value="1553"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.8"/>
                    <measurement group_id="O2" value="26.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7962</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
            <estimate_desc>HR for Herceptin 2-Year Arm versus Herceptin 1-Year Arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DFS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 10-Year Maximum Follow-Up</title>
        <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.</description>
        <time_frame>Years 3, 5, 7, 8, 9, 10</time_frame>
        <population>FAS Population 1Y2Y</population>
        <group_list>
          <group group_id="O1">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>DFS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 10-Year Maximum Follow-Up</title>
          <description>DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events.</description>
          <population>FAS Population 1Y2Y</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1552"/>
                <count group_id="O2" value="1553"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.7" lower_limit="85.0" upper_limit="88.4"/>
                    <measurement group_id="O2" value="89.0" lower_limit="87.4" upper_limit="90.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.0" lower_limit="79.0" upper_limit="82.9"/>
                    <measurement group_id="O2" value="81.6" lower_limit="79.6" upper_limit="83.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.2" lower_limit="75.1" upper_limit="79.3"/>
                    <measurement group_id="O2" value="77.4" lower_limit="75.3" upper_limit="79.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.9" lower_limit="73.8" upper_limit="78.1"/>
                    <measurement group_id="O2" value="75.5" lower_limit="73.3" upper_limit="77.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" lower_limit="72.8" upper_limit="77.2"/>
                    <measurement group_id="O2" value="73.9" lower_limit="71.7" upper_limit="76.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.9" lower_limit="71.7" upper_limit="76.1"/>
                    <measurement group_id="O2" value="73.1" lower_limit="70.8" upper_limit="75.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Overall Survival (OS) Events in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up</title>
        <description>OS events referred to death from any cause. The percentage of participants who died was reported. The analysis of the Herceptin 1-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed by the Sponsor in 2006 following database cleaning. The analysis of the Herceptin 2-Year Arm against the Observation Arm was performed for an IDMC in 2005 at a time the Sponsor was blinded. Therefore, these data are reported under a separate Outcome Measure.</description>
        <time_frame>From Baseline until time of event (median of 1 year)</time_frame>
        <population>FAS Population. The &quot;Number of Participants Analyzed&quot; reflects the number with data for the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Observation Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin was provided.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Overall Survival (OS) Events in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up</title>
          <description>OS events referred to death from any cause. The percentage of participants who died was reported. The analysis of the Herceptin 1-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed by the Sponsor in 2006 following database cleaning. The analysis of the Herceptin 2-Year Arm against the Observation Arm was performed for an IDMC in 2005 at a time the Sponsor was blinded. Therefore, these data are reported under a separate Outcome Measure.</description>
          <population>FAS Population. The &quot;Number of Participants Analyzed&quot; reflects the number with data for the endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1693"/>
                <count group_id="O2" value="1693"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2379</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
            <estimate_desc>HR for Herceptin 1-Year Arm versus Observation Arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With OS Events in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up</title>
        <description>OS events referred to death from any cause. The percentage of participants who died was reported. The analysis of the Herceptin 2-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed for an IDMC in 2005 at a time the Sponsor was blinded. The analysis of the Herceptin 1-Year Arm against the Observation Arm was performed by the Sponsor in 2006 following database cleaning. Therefore, these data are reported under a separate Outcome Measure.</description>
        <time_frame>From Baseline until time of event (median of 1 year)</time_frame>
        <population>FAS Population. The &quot;Number of Participants Analyzed&quot; reflects the number with data for the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Observation Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin was provided.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With OS Events in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up</title>
          <description>OS events referred to death from any cause. The percentage of participants who died was reported. The analysis of the Herceptin 2-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed for an IDMC in 2005 at a time the Sponsor was blinded. The analysis of the Herceptin 1-Year Arm against the Observation Arm was performed by the Sponsor in 2006 following database cleaning. Therefore, these data are reported under a separate Outcome Measure.</description>
          <population>FAS Population. The &quot;Number of Participants Analyzed&quot; reflects the number with data for the endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1693"/>
                <count group_id="O2" value="1694"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                    <measurement group_id="O2" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.28</ci_lower_limit>
            <ci_upper_limit>0.79</ci_upper_limit>
            <estimate_desc>HR for Herceptin 2-Year Arm versus Observation Arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OS Rate According to Kaplan-Meier Analysis in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up</title>
        <description>OS events referred to death from any cause. The percentage of participants alive (i.e., the OS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 1-year median follow-up analysis. The analysis of the Herceptin 1-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed by the Sponsor in 2006 following database cleaning. The analysis of the Herceptin 2-Year Arm against the Observation Arm was performed for an IDMC in 2005 at a time the Sponsor was blinded. Therefore, these data are reported under a separate Outcome Measure.</description>
        <time_frame>Year 2</time_frame>
        <population>FAS Population. The &quot;Number of Participants Analyzed&quot; reflects the number with data for the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Observation Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin was provided.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>OS Rate According to Kaplan-Meier Analysis in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up</title>
          <description>OS events referred to death from any cause. The percentage of participants alive (i.e., the OS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 1-year median follow-up analysis. The analysis of the Herceptin 1-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed by the Sponsor in 2006 following database cleaning. The analysis of the Herceptin 2-Year Arm against the Observation Arm was performed for an IDMC in 2005 at a time the Sponsor was blinded. Therefore, these data are reported under a separate Outcome Measure.</description>
          <population>FAS Population. The &quot;Number of Participants Analyzed&quot; reflects the number with data for the endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1693"/>
                <count group_id="O2" value="1693"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.98" lower_limit="93" upper_limit="97"/>
                    <measurement group_id="O2" value="95.88" lower_limit="94" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OS Rate According to Kaplan-Meier Analysis in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up</title>
        <description>OS events referred to death from any cause. The percentage of participants alive (i.e., the OS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 1-year median follow-up analysis. The analysis of the Herceptin 2-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed for an IDMC in 2005 at a time the Sponsor was blinded. The analysis of the Herceptin 1-Year Arm against the Observation Arm was performed by the Sponsor in 2006 following database cleaning. Therefore, these data are reported under a separate Outcome Measure.</description>
        <time_frame>Year 2</time_frame>
        <population>FAS Population. The &quot;Number of Participants Analyzed&quot; reflects the number with data for the endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Observation Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin was provided.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>OS Rate According to Kaplan-Meier Analysis in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up</title>
          <description>OS events referred to death from any cause. The percentage of participants alive (i.e., the OS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 1-year median follow-up analysis. The analysis of the Herceptin 2-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed for an IDMC in 2005 at a time the Sponsor was blinded. The analysis of the Herceptin 1-Year Arm against the Observation Arm was performed by the Sponsor in 2006 following database cleaning. Therefore, these data are reported under a separate Outcome Measure.</description>
          <population>FAS Population. The &quot;Number of Participants Analyzed&quot; reflects the number with data for the endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1693"/>
                <count group_id="O2" value="1694"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.39" lower_limit="92" upper_limit="97"/>
                    <measurement group_id="O2" value="97.28" lower_limit="96" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With OS Events Compared to Observation: 8-Year Median Follow-Up</title>
        <description>OS events referred to death from any cause. The percentage of participants who died was reported.</description>
        <time_frame>From Baseline until time of event (median of 8 years)</time_frame>
        <population>FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>Observation Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin was provided.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
          <group group_id="O3">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With OS Events Compared to Observation: 8-Year Median Follow-Up</title>
          <description>OS events referred to death from any cause. The percentage of participants who died was reported.</description>
          <population>FAS Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1697"/>
                <count group_id="O2" value="1702"/>
                <count group_id="O3" value="1700"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.6"/>
                    <measurement group_id="O2" value="16.3"/>
                    <measurement group_id="O3" value="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>0.88</ci_upper_limit>
            <estimate_desc>HR for Herceptin 1-Year Arm versus Observation Arm.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>0.86</ci_upper_limit>
            <estimate_desc>HR for Herceptin 2-Year Arm versus Observation Arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OS Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up</title>
        <description>OS events referred to death from any cause. The percentage of participants alive (i.e., the OS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.</description>
        <time_frame>Years 3, 5, 7, 8</time_frame>
        <population>FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>Observation Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin was provided.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
          <group group_id="O3">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>OS Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up</title>
          <description>OS events referred to death from any cause. The percentage of participants alive (i.e., the OS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.</description>
          <population>FAS Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1697"/>
                <count group_id="O2" value="1702"/>
                <count group_id="O3" value="1700"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.7" lower_limit="89.3" upper_limit="92.1"/>
                    <measurement group_id="O2" value="92.7" lower_limit="91.5" upper_limit="94.0"/>
                    <measurement group_id="O3" value="94.4" lower_limit="93.3" upper_limit="95.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.5" lower_limit="82.8" upper_limit="86.3"/>
                    <measurement group_id="O2" value="86.9" lower_limit="85.2" upper_limit="88.5"/>
                    <measurement group_id="O3" value="88.7" lower_limit="87.2" upper_limit="90.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.5" lower_limit="77.5" upper_limit="81.5"/>
                    <measurement group_id="O2" value="83.9" lower_limit="82.1" upper_limit="85.7"/>
                    <measurement group_id="O3" value="84.6" lower_limit="82.9" upper_limit="86.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.4" lower_limit="75.2" upper_limit="79.5"/>
                    <measurement group_id="O2" value="82.7" lower_limit="80.8" upper_limit="84.6"/>
                    <measurement group_id="O3" value="82.4" lower_limit="80.4" upper_limit="84.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With OS Events Compared to Observation: 11-Year Median Follow-Up</title>
        <description>OS events referred to death from any cause. The percentage of participants who died was reported.</description>
        <time_frame>From Baseline until time of event (median of 11 years)</time_frame>
        <population>FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>Observation Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin was provided.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
          <group group_id="O3">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With OS Events Compared to Observation: 11-Year Median Follow-Up</title>
          <description>OS events referred to death from any cause. The percentage of participants who died was reported.</description>
          <population>FAS Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1697"/>
                <count group_id="O2" value="1702"/>
                <count group_id="O3" value="1700"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9"/>
                    <measurement group_id="O2" value="18.8"/>
                    <measurement group_id="O3" value="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>0.86</ci_upper_limit>
            <estimate_desc>HR for Herceptin 1-Year Arm versus Observation Arm.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>0.83</ci_upper_limit>
            <estimate_desc>HR for Herceptin 2-Year Arm versus Observation Arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OS Rate According to Kaplan-Meier Analysis Compared to Observation: 11-Year Median Follow-Up</title>
        <description>OS events referred to death from any cause. The percentage of participants alive (i.e., the OS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with an 11-year median follow-up for OS events.</description>
        <time_frame>Years 3, 5, 7, 9, 10, 11, 12</time_frame>
        <population>FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>Observation Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin was provided.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
          <group group_id="O3">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>OS Rate According to Kaplan-Meier Analysis Compared to Observation: 11-Year Median Follow-Up</title>
          <description>OS events referred to death from any cause. The percentage of participants alive (i.e., the OS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with an 11-year median follow-up for OS events.</description>
          <population>FAS Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1697"/>
                <count group_id="O2" value="1702"/>
                <count group_id="O3" value="1700"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.7" lower_limit="89.3" upper_limit="92.1"/>
                    <measurement group_id="O2" value="92.7" lower_limit="91.5" upper_limit="94.0"/>
                    <measurement group_id="O3" value="94.4" lower_limit="93.3" upper_limit="95.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.5" lower_limit="82.8" upper_limit="86.3"/>
                    <measurement group_id="O2" value="86.9" lower_limit="85.2" upper_limit="88.5"/>
                    <measurement group_id="O3" value="88.7" lower_limit="87.2" upper_limit="90.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.4" lower_limit="77.4" upper_limit="81.4"/>
                    <measurement group_id="O2" value="83.8" lower_limit="82.0" upper_limit="85.6"/>
                    <measurement group_id="O3" value="84.7" lower_limit="82.9" upper_limit="86.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.5" lower_limit="74.4" upper_limit="78.6"/>
                    <measurement group_id="O2" value="81.9" lower_limit="80.0" upper_limit="83.8"/>
                    <measurement group_id="O3" value="81.8" lower_limit="80.0" upper_limit="83.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" lower_limit="72.9" upper_limit="77.2"/>
                    <measurement group_id="O2" value="80.7" lower_limit="78.8" upper_limit="82.6"/>
                    <measurement group_id="O3" value="81.0" lower_limit="79.0" upper_limit="82.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.7" lower_limit="71.5" upper_limit="76.0"/>
                    <measurement group_id="O2" value="80.0" lower_limit="78.1" upper_limit="82.0"/>
                    <measurement group_id="O3" value="80.3" lower_limit="78.3" upper_limit="82.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.9" lower_limit="70.4" upper_limit="75.3"/>
                    <measurement group_id="O2" value="79.4" lower_limit="77.3" upper_limit="81.5"/>
                    <measurement group_id="O3" value="79.5" lower_limit="77.4" upper_limit="81.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With OS Events in 1-Year Versus 2-Year Herceptin: 11-Year Median Follow-Up</title>
        <description>OS events referred to death from any cause. The percentage of participants who died was reported.</description>
        <time_frame>From Baseline until time of event (median of 11 years)</time_frame>
        <population>FAS Population 1Y2Y</population>
        <group_list>
          <group group_id="O1">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With OS Events in 1-Year Versus 2-Year Herceptin: 11-Year Median Follow-Up</title>
          <description>OS events referred to death from any cause. The percentage of participants who died was reported.</description>
          <population>FAS Population 1Y2Y</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1552"/>
                <count group_id="O2" value="1553"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7"/>
                    <measurement group_id="O2" value="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9156</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
            <estimate_desc>HR for Herceptin 2-Year Arm versus Herceptin 1-Year Arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 11-Year Median Follow-Up</title>
        <description>OS events referred to death from any cause. The percentage of participants alive (i.e., the OS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with an 11-year median follow-up for OS events.</description>
        <time_frame>Years 3, 5, 7, 9, 10, 11, 12</time_frame>
        <population>FAS Population 1Y2Y</population>
        <group_list>
          <group group_id="O1">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>OS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 11-Year Median Follow-Up</title>
          <description>OS events referred to death from any cause. The percentage of participants alive (i.e., the OS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with an 11-year median follow-up for OS events.</description>
          <population>FAS Population 1Y2Y</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1552"/>
                <count group_id="O2" value="1553"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.5" lower_limit="95.6" upper_limit="97.4"/>
                    <measurement group_id="O2" value="97.4" lower_limit="96.6" upper_limit="98.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.4" lower_limit="90.0" upper_limit="92.8"/>
                    <measurement group_id="O2" value="92.6" lower_limit="91.2" upper_limit="93.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.6" lower_limit="87.0" upper_limit="90.2"/>
                    <measurement group_id="O2" value="88.7" lower_limit="87.1" upper_limit="90.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.7" lower_limit="85.0" upper_limit="88.5"/>
                    <measurement group_id="O2" value="85.9" lower_limit="84.2" upper_limit="87.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.4" lower_limit="83.6" upper_limit="87.2"/>
                    <measurement group_id="O2" value="85.1" lower_limit="83.3" upper_limit="86.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.7" lower_limit="82.9" upper_limit="86.6"/>
                    <measurement group_id="O2" value="84.4" lower_limit="82.5" upper_limit="86.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.1" lower_limit="82.1" upper_limit="86.1"/>
                    <measurement group_id="O2" value="83.6" lower_limit="81.5" upper_limit="85.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Recurrence-Free Survival (RFS) Events Compared to Observation: 8-Year Median Follow-Up</title>
        <description>RFS events included local, regional, or distant tumor recurrence. The percentage of participants with at least one RFS event was reported.</description>
        <time_frame>From Baseline until time of event (median of 8 years)</time_frame>
        <population>FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>Observation Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin was provided.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
          <group group_id="O3">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Recurrence-Free Survival (RFS) Events Compared to Observation: 8-Year Median Follow-Up</title>
          <description>RFS events included local, regional, or distant tumor recurrence. The percentage of participants with at least one RFS event was reported.</description>
          <population>FAS Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1697"/>
                <count group_id="O2" value="1702"/>
                <count group_id="O3" value="1700"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.8"/>
                    <measurement group_id="O2" value="23.4"/>
                    <measurement group_id="O3" value="22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>0.83</ci_upper_limit>
            <estimate_desc>HR for Herceptin 1-Year Arm versus Observation Arm.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>0.79</ci_upper_limit>
            <estimate_desc>HR for Herceptin 2-Year Arm versus Observation Arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>RFS Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up</title>
        <description>RFS events included local, regional, or distant tumor recurrence. The percentage of participants free of RFS events (i.e., the RFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.</description>
        <time_frame>Years 3, 5, 7, 8</time_frame>
        <population>FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>Observation Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin was provided.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
          <group group_id="O3">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>RFS Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up</title>
          <description>RFS events included local, regional, or distant tumor recurrence. The percentage of participants free of RFS events (i.e., the RFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.</description>
          <population>FAS Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1697"/>
                <count group_id="O2" value="1702"/>
                <count group_id="O3" value="1700"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.4" lower_limit="74.3" upper_limit="78.4"/>
                    <measurement group_id="O2" value="82.7" lower_limit="80.9" upper_limit="84.6"/>
                    <measurement group_id="O3" value="86.0" lower_limit="84.3" upper_limit="87.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.9" lower_limit="69.7" upper_limit="74.1"/>
                    <measurement group_id="O2" value="78.4" lower_limit="76.4" upper_limit="80.4"/>
                    <measurement group_id="O3" value="79.9" lower_limit="77.9" upper_limit="81.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.0" lower_limit="66.7" upper_limit="71.3"/>
                    <measurement group_id="O2" value="75.7" lower_limit="73.6" upper_limit="77.8"/>
                    <measurement group_id="O3" value="76.7" lower_limit="74.6" upper_limit="78.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.4" lower_limit="66.1" upper_limit="70.7"/>
                    <measurement group_id="O2" value="75.1" lower_limit="72.9" upper_limit="77.2"/>
                    <measurement group_id="O3" value="75.8" lower_limit="73.6" upper_limit="77.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With RFS Events in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up</title>
        <description>RFS events included local, regional, or distant tumor recurrence. The percentage of participants with at least one RFS event was reported.</description>
        <time_frame>From Baseline until time of event (median of 8 years)</time_frame>
        <population>FAS Population 1Y2Y</population>
        <group_list>
          <group group_id="O1">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With RFS Events in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up</title>
          <description>RFS events included local, regional, or distant tumor recurrence. The percentage of participants with at least one RFS event was reported.</description>
          <population>FAS Population 1Y2Y</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1552"/>
                <count group_id="O2" value="1553"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.7"/>
                    <measurement group_id="O2" value="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4755</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
            <estimate_desc>HR for Herceptin 2-Year Arm versus Herceptin 1-Year Arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>RFS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up</title>
        <description>RFS events included local, regional, or distant tumor recurrence. The percentage of participants free of RFS events (i.e., the RFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.</description>
        <time_frame>Years 3, 5, 7, 8</time_frame>
        <population>FAS Population 1Y2Y</population>
        <group_list>
          <group group_id="O1">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>RFS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up</title>
          <description>RFS events included local, regional, or distant tumor recurrence. The percentage of participants free of RFS events (i.e., the RFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.</description>
          <population>FAS Population 1Y2Y</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1552"/>
                <count group_id="O2" value="1553"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.7" lower_limit="86.0" upper_limit="89.3"/>
                    <measurement group_id="O2" value="90.9" lower_limit="89.4" upper_limit="92.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.1" lower_limit="81.2" upper_limit="85.0"/>
                    <measurement group_id="O2" value="84.5" lower_limit="82.7" upper_limit="86.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.2" lower_limit="78.2" upper_limit="82.3"/>
                    <measurement group_id="O2" value="81.3" lower_limit="79.3" upper_limit="83.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.6" lower_limit="77.5" upper_limit="81.6"/>
                    <measurement group_id="O2" value="80.3" lower_limit="78.2" upper_limit="82.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Distant Disease-Free Survival (DDFS) Events Compared to Observation: 8-Year Median Follow-Up</title>
        <description>DDFS events included distant tumor recurrence, second primary cancer, or contralateral breast cancer. The percentage of participants with at least one DDFS event was reported.</description>
        <time_frame>From Baseline until time of event (median of 8 years)</time_frame>
        <population>FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>Observation Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin was provided.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
          <group group_id="O3">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Distant Disease-Free Survival (DDFS) Events Compared to Observation: 8-Year Median Follow-Up</title>
          <description>DDFS events included distant tumor recurrence, second primary cancer, or contralateral breast cancer. The percentage of participants with at least one DDFS event was reported.</description>
          <population>FAS Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1697"/>
                <count group_id="O2" value="1702"/>
                <count group_id="O3" value="1700"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.8"/>
                    <measurement group_id="O2" value="23.4"/>
                    <measurement group_id="O3" value="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>0.87</ci_upper_limit>
            <estimate_desc>HR for Herceptin 1-Year Arm versus Observation Arm.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
            <estimate_desc>HR for Herceptin 2-Year Arm versus Observation Arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DDFS Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up</title>
        <description>DDFS events included distant tumor recurrence, second primary cancer, or contralateral breast cancer. The percentage of participants free of DDFS events (i.e., the DDFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.</description>
        <time_frame>Years 3, 5, 7, 8</time_frame>
        <population>FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>Observation Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin was provided.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
          <group group_id="O3">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>DDFS Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up</title>
          <description>DDFS events included distant tumor recurrence, second primary cancer, or contralateral breast cancer. The percentage of participants free of DDFS events (i.e., the DDFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.</description>
          <population>FAS Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1697"/>
                <count group_id="O2" value="1702"/>
                <count group_id="O3" value="1700"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.6" lower_limit="76.6" upper_limit="80.6"/>
                    <measurement group_id="O2" value="84.4" lower_limit="82.7" upper_limit="86.2"/>
                    <measurement group_id="O3" value="85.9" lower_limit="84.2" upper_limit="87.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.2" lower_limit="72.1" upper_limit="76.4"/>
                    <measurement group_id="O2" value="79.6" lower_limit="77.6" upper_limit="81.6"/>
                    <measurement group_id="O3" value="80.2" lower_limit="78.2" upper_limit="82.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.8" lower_limit="68.6" upper_limit="73.1"/>
                    <measurement group_id="O2" value="76.7" lower_limit="74.6" upper_limit="78.8"/>
                    <measurement group_id="O3" value="76.7" lower_limit="74.6" upper_limit="78.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.6" lower_limit="67.3" upper_limit="71.9"/>
                    <measurement group_id="O2" value="75.5" lower_limit="73.4" upper_limit="77.6"/>
                    <measurement group_id="O3" value="75.6" lower_limit="73.4" upper_limit="77.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With DDFS Events in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up</title>
        <description>DDFS events included distant tumor recurrence, second primary cancer, or contralateral breast cancer. The percentage of participants with at least one DDFS event was reported.</description>
        <time_frame>From Baseline until time of event (median of 8 years)</time_frame>
        <population>FAS Population 1Y2Y</population>
        <group_list>
          <group group_id="O1">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With DDFS Events in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up</title>
          <description>DDFS events included distant tumor recurrence, second primary cancer, or contralateral breast cancer. The percentage of participants with at least one DDFS event was reported.</description>
          <population>FAS Population 1Y2Y</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1552"/>
                <count group_id="O2" value="1553"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5"/>
                    <measurement group_id="O2" value="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9626</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
            <estimate_desc>HR for Herceptin 2-Year Arm versus Herceptin 1-Year Arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DDFS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up</title>
        <description>DDFS events included distant tumor recurrence, second primary cancer, or contralateral breast cancer. The percentage of participants free of DDFS events (i.e., the DDFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.</description>
        <time_frame>Years 3, 5, 7, 8</time_frame>
        <population>FAS Population 1Y2Y</population>
        <group_list>
          <group group_id="O1">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>DDFS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up</title>
          <description>DDFS events included distant tumor recurrence, second primary cancer, or contralateral breast cancer. The percentage of participants free of DDFS events (i.e., the DDFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.</description>
          <population>FAS Population 1Y2Y</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1552"/>
                <count group_id="O2" value="1553"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.4" lower_limit="87.9" upper_limit="91.0"/>
                    <measurement group_id="O2" value="90.8" lower_limit="89.4" upper_limit="92.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.5" lower_limit="82.7" upper_limit="86.3"/>
                    <measurement group_id="O2" value="84.7" lower_limit="82.9" upper_limit="86.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.4" lower_limit="79.5" upper_limit="83.4"/>
                    <measurement group_id="O2" value="81.1" lower_limit="79.1" upper_limit="83.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.1" lower_limit="78.1" upper_limit="82.2"/>
                    <measurement group_id="O2" value="79.9" lower_limit="77.8" upper_limit="81.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Tumor Recurrence (TR) Compared to Observation: 8-Year Median Follow-Up</title>
        <description>The percentage of participants with TR of the present breast cancer was reported. TR included local, regional, or distant tumor ignoring contralateral breast cancer and second non-breast malignancy.</description>
        <time_frame>From Baseline until time of event (median of 8 years)</time_frame>
        <population>FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>Observation Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin was provided.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
          <group group_id="O3">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Tumor Recurrence (TR) Compared to Observation: 8-Year Median Follow-Up</title>
          <description>The percentage of participants with TR of the present breast cancer was reported. TR included local, regional, or distant tumor ignoring contralateral breast cancer and second non-breast malignancy.</description>
          <population>FAS Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1697"/>
                <count group_id="O2" value="1702"/>
                <count group_id="O3" value="1700"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.8"/>
                    <measurement group_id="O2" value="23.4"/>
                    <measurement group_id="O3" value="22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>0.83</ci_upper_limit>
            <estimate_desc>HR for Herceptin 1-Year Arm versus Observation Arm.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>0.79</ci_upper_limit>
            <estimate_desc>HR for Herceptin 2-Year Arm versus Observation Arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TR-Free Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up</title>
        <description>The percentage of participants without TR of the present breast cancer (i.e., the TR-free rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis. TR included local, regional, or distant tumor ignoring contralateral breast cancer and second non-breast malignancy.</description>
        <time_frame>Years 3, 5, 7, 8</time_frame>
        <population>FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>Observation Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin was provided.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
          <group group_id="O3">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>TR-Free Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up</title>
          <description>The percentage of participants without TR of the present breast cancer (i.e., the TR-free rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis. TR included local, regional, or distant tumor ignoring contralateral breast cancer and second non-breast malignancy.</description>
          <population>FAS Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1697"/>
                <count group_id="O2" value="1702"/>
                <count group_id="O3" value="1700"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.5" lower_limit="74.4" upper_limit="78.5"/>
                    <measurement group_id="O2" value="82.8" lower_limit="81.0" upper_limit="84.6"/>
                    <measurement group_id="O3" value="86.1" lower_limit="84.4" upper_limit="87.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.1" lower_limit="69.9" upper_limit="74.3"/>
                    <measurement group_id="O2" value="78.6" lower_limit="76.6" upper_limit="80.6"/>
                    <measurement group_id="O3" value="80.1" lower_limit="78.2" upper_limit="82.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.2" lower_limit="67.0" upper_limit="71.5"/>
                    <measurement group_id="O2" value="75.9" lower_limit="73.9" upper_limit="78.0"/>
                    <measurement group_id="O3" value="77.0" lower_limit="75.0" upper_limit="79.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.6" lower_limit="66.4" upper_limit="70.9"/>
                    <measurement group_id="O2" value="75.3" lower_limit="73.2" upper_limit="77.4"/>
                    <measurement group_id="O3" value="76.2" lower_limit="74.1" upper_limit="78.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With TR in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up</title>
        <description>The percentage of participants with TR of the present breast cancer was reported. TR included local, regional, or distant tumor ignoring contralateral breast cancer and second non-breast malignancy.</description>
        <time_frame>From Baseline until time of event (median of 8 years)</time_frame>
        <population>FAS Population 1Y2Y</population>
        <group_list>
          <group group_id="O1">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With TR in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up</title>
          <description>The percentage of participants with TR of the present breast cancer was reported. TR included local, regional, or distant tumor ignoring contralateral breast cancer and second non-breast malignancy.</description>
          <population>FAS Population 1Y2Y</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1552"/>
                <count group_id="O2" value="1553"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.7"/>
                    <measurement group_id="O2" value="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4500</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
            <estimate_desc>HR for Herceptin 2-Year Arm versus Herceptin 1-Year Arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TR-Free Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up</title>
        <description>The percentage of participants without TR of the present breast cancer (i.e., the TR-free rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis. TR included local, regional, or distant tumor ignoring contralateral breast cancer and second non-breast malignancy.</description>
        <time_frame>Years 3, 5, 7, 8</time_frame>
        <population>FAS Population 1Y2Y</population>
        <group_list>
          <group group_id="O1">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>TR-Free Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up</title>
          <description>The percentage of participants without TR of the present breast cancer (i.e., the TR-free rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis. TR included local, regional, or distant tumor ignoring contralateral breast cancer and second non-breast malignancy.</description>
          <population>FAS Population 1Y2Y</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1552"/>
                <count group_id="O2" value="1553"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.7" lower_limit="86.1" upper_limit="89.4"/>
                    <measurement group_id="O2" value="90.9" lower_limit="89.5" upper_limit="92.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.2" lower_limit="81.3" upper_limit="85.1"/>
                    <measurement group_id="O2" value="84.7" lower_limit="82.9" upper_limit="86.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.4" lower_limit="78.4" upper_limit="82.4"/>
                    <measurement group_id="O2" value="81.5" lower_limit="79.6" upper_limit="83.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.8" lower_limit="77.7" upper_limit="81.8"/>
                    <measurement group_id="O2" value="80.6" lower_limit="78.6" upper_limit="82.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Distant Tumor Recurrence (DTR) Compared to Observation: 8-Year Median Follow-Up</title>
        <description>The percentage of participants with DTR was reported. DTR included distant tumors ignoring local and regional recurrences, contralateral breast cancer, and second non-breast malignancy.</description>
        <time_frame>From Baseline until time of event (median of 8 years)</time_frame>
        <population>FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>Observation Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin was provided.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
          <group group_id="O3">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Distant Tumor Recurrence (DTR) Compared to Observation: 8-Year Median Follow-Up</title>
          <description>The percentage of participants with DTR was reported. DTR included distant tumors ignoring local and regional recurrences, contralateral breast cancer, and second non-breast malignancy.</description>
          <population>FAS Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1697"/>
                <count group_id="O2" value="1702"/>
                <count group_id="O3" value="1700"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.3"/>
                    <measurement group_id="O2" value="19.4"/>
                    <measurement group_id="O3" value="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>0.83</ci_upper_limit>
            <estimate_desc>HR for Herceptin 1-Year Arm versus Observation Arm.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>0.79</ci_upper_limit>
            <estimate_desc>HR for Herceptin 2-Year Arm versus Observation Arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DTR-Free Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up</title>
        <description>The percentage of participants without DTR (i.e., the DTR-free rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis. DTR included distant tumors ignoring local and regional recurrences, contralateral breast cancer, and second non-breast malignancy.</description>
        <time_frame>Years 3, 5, 7, 8</time_frame>
        <population>FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>Observation Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin was provided.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
          <group group_id="O3">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>DTR-Free Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up</title>
          <description>The percentage of participants without DTR (i.e., the DTR-free rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis. DTR included distant tumors ignoring local and regional recurrences, contralateral breast cancer, and second non-breast malignancy.</description>
          <population>FAS Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1697"/>
                <count group_id="O2" value="1702"/>
                <count group_id="O3" value="1700"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.8" lower_limit="77.8" upper_limit="81.7"/>
                    <measurement group_id="O2" value="85.9" lower_limit="84.2" upper_limit="87.6"/>
                    <measurement group_id="O3" value="88.1" lower_limit="86.5" upper_limit="89.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.5" lower_limit="74.4" upper_limit="78.5"/>
                    <measurement group_id="O2" value="82.1" lower_limit="80.2" upper_limit="84.0"/>
                    <measurement group_id="O3" value="83.4" lower_limit="81.5" upper_limit="85.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.0" lower_limit="71.8" upper_limit="76.1"/>
                    <measurement group_id="O2" value="80.1" lower_limit="78.2" upper_limit="82.1"/>
                    <measurement group_id="O3" value="80.7" lower_limit="78.8" upper_limit="82.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.3" lower_limit="71.1" upper_limit="75.5"/>
                    <measurement group_id="O2" value="79.5" lower_limit="77.5" upper_limit="81.5"/>
                    <measurement group_id="O3" value="80.3" lower_limit="78.3" upper_limit="82.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With DTR in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up</title>
        <description>The percentage of participants with DTR was reported. DTR included distant tumors ignoring local and regional recurrences, contralateral breast cancer, and second non-breast malignancy.</description>
        <time_frame>From Baseline until time of event (median of 8 years)</time_frame>
        <population>FAS Population 1Y2Y</population>
        <group_list>
          <group group_id="O1">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With DTR in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up</title>
          <description>The percentage of participants with DTR was reported. DTR included distant tumors ignoring local and regional recurrences, contralateral breast cancer, and second non-breast malignancy.</description>
          <population>FAS Population 1Y2Y</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1552"/>
                <count group_id="O2" value="1553"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5"/>
                    <measurement group_id="O2" value="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6823</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
            <estimate_desc>HR for Herceptin 2-Year Arm versus Herceptin 1-Year Arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DTR-Free Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up</title>
        <description>The percentage of participants without DTR (i.e., the DTR-free rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis. DTR included distant tumors ignoring local and regional recurrences, contralateral breast cancer, and second non-breast malignancy.</description>
        <time_frame>Years 3, 5, 7, 8</time_frame>
        <population>FAS Population 1Y2Y</population>
        <group_list>
          <group group_id="O1">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>DTR-Free Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up</title>
          <description>The percentage of participants without DTR (i.e., the DTR-free rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis. DTR included distant tumors ignoring local and regional recurrences, contralateral breast cancer, and second non-breast malignancy.</description>
          <population>FAS Population 1Y2Y</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1552"/>
                <count group_id="O2" value="1553"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.5" lower_limit="89.0" upper_limit="91.9"/>
                    <measurement group_id="O2" value="92.4" lower_limit="91.1" upper_limit="93.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.7" lower_limit="85.0" upper_limit="88.4"/>
                    <measurement group_id="O2" value="87.5" lower_limit="85.8" upper_limit="89.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.6" lower_limit="82.8" upper_limit="86.4"/>
                    <measurement group_id="O2" value="84.9" lower_limit="83.1" upper_limit="86.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.9" lower_limit="82.1" upper_limit="85.8"/>
                    <measurement group_id="O2" value="84.4" lower_limit="82.6" upper_limit="86.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Restricted Disease-Free Survival (RDFS) Events in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up</title>
        <description>RDFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer, or death from any cause. The percentage of participants with at least one RDFS event was reported.</description>
        <time_frame>From Baseline until time of event (median of 8 years)</time_frame>
        <population>FAS Population 1Y2Y. In contrast to other study endpoints, RDFS compared to the Observation Arm was not a planned endpoint according to study protocol. Only RDFS in Herceptin 1-Year Arm versus Herceptin 2-Year Arm was a planned endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Restricted Disease-Free Survival (RDFS) Events in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up</title>
          <description>RDFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer, or death from any cause. The percentage of participants with at least one RDFS event was reported.</description>
          <population>FAS Population 1Y2Y. In contrast to other study endpoints, RDFS compared to the Observation Arm was not a planned endpoint according to study protocol. Only RDFS in Herceptin 1-Year Arm versus Herceptin 2-Year Arm was a planned endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1552"/>
                <count group_id="O2" value="1553"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2"/>
                    <measurement group_id="O2" value="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7251</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
            <estimate_desc>HR for Herceptin 2-Year Arm versus Herceptin 1-Year Arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>RDFS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up</title>
        <description>RDFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer, or death from any cause. The percentage of participants free of RDFS events (i.e., the RDFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.</description>
        <time_frame>Years 3, 5, 7, 8</time_frame>
        <population>FAS Population 1Y2Y. In contrast to other study endpoints, RDFS compared to the Observation Arm was not a planned endpoint according to study protocol. Only RDFS in Herceptin 1-Year Arm versus Herceptin 2-Year Arm was a planned endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>RDFS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up</title>
          <description>RDFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer, or death from any cause. The percentage of participants free of RDFS events (i.e., the RDFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis.</description>
          <population>FAS Population 1Y2Y. In contrast to other study endpoints, RDFS compared to the Observation Arm was not a planned endpoint according to study protocol. Only RDFS in Herceptin 1-Year Arm versus Herceptin 2-Year Arm was a planned endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1552"/>
                <count group_id="O2" value="1553"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.3" lower_limit="85.6" upper_limit="89.0"/>
                    <measurement group_id="O2" value="89.9" lower_limit="88.4" upper_limit="91.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.9" lower_limit="79.9" upper_limit="83.8"/>
                    <measurement group_id="O2" value="83.0" lower_limit="81.1" upper_limit="84.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.5" lower_limit="76.4" upper_limit="80.6"/>
                    <measurement group_id="O2" value="78.9" lower_limit="76.9" upper_limit="81.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.2" lower_limit="75.1" upper_limit="79.3"/>
                    <measurement group_id="O2" value="77.7" lower_limit="75.5" upper_limit="79.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Primary Cardiac Endpoint Events Compared to Observation: 10-Year Maximum Follow-Up</title>
        <description>Primary cardiac endpoint events included the occurrence of any of the following between randomization and new therapy for recurrent disease: symptomatic New York Heart Association (NYHA) Class III or IV congestive heart failure (CHF) confirmed by a cardiologist with a drop in left ventricular ejection fraction (LVEF) at least 10 percentage points from Baseline and to a value less than (&lt;) 50%, and documentation of definite or probable cardiac death. Definite cardiac death included CHF, myocardial infarction, or primary arrhythmia. Probable cardiac death included unexpected sudden death within 24 hours of a cardiac event (syncope, cardiac arrest, chest pain, infarction, arrhythmia) without documented etiology. The percentage of participants with at least one primary cardiac endpoint event was reported. The 95% CI was calculated by the Pearson-Clopper method for a one-sample binomial.</description>
        <time_frame>From Baseline until time of event (maximum up to 10 years)</time_frame>
        <population>Safety Population: All participants randomized/enrolled in the study according to actual treatment received. Hence, participants assigned to Herceptin who received no study treatment were analyzed in the Observation Arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Observation Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin was provided.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
          <group group_id="O3">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Primary Cardiac Endpoint Events Compared to Observation: 10-Year Maximum Follow-Up</title>
          <description>Primary cardiac endpoint events included the occurrence of any of the following between randomization and new therapy for recurrent disease: symptomatic New York Heart Association (NYHA) Class III or IV congestive heart failure (CHF) confirmed by a cardiologist with a drop in left ventricular ejection fraction (LVEF) at least 10 percentage points from Baseline and to a value less than (&lt;) 50%, and documentation of definite or probable cardiac death. Definite cardiac death included CHF, myocardial infarction, or primary arrhythmia. Probable cardiac death included unexpected sudden death within 24 hours of a cardiac event (syncope, cardiac arrest, chest pain, infarction, arrhythmia) without documented etiology. The percentage of participants with at least one primary cardiac endpoint event was reported. The 95% CI was calculated by the Pearson-Clopper method for a one-sample binomial.</description>
          <population>Safety Population: All participants randomized/enrolled in the study according to actual treatment received. Hence, participants assigned to Herceptin who received no study treatment were analyzed in the Observation Arm.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1744"/>
                <count group_id="O2" value="1682"/>
                <count group_id="O3" value="1673"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" lower_limit="0.01" upper_limit="0.41"/>
                    <measurement group_id="O2" value="1.07" lower_limit="0.64" upper_limit="1.69"/>
                    <measurement group_id="O3" value="1.02" lower_limit="0.59" upper_limit="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Secondary Cardiac Endpoint Events Compared to Observation: 10-Year Maximum Follow-Up</title>
        <description>Secondary cardiac endpoint events included NYHA Class I or II CHF with a drop in LVEF measured by multiple-gated acquisition or electrocardiogram, unless the subsequent assessment of LVEF indicated a return to levels that did not meet the definition of a significant LVEF drop. A significant LVEF drop was defined as an absolute reduction of at least 10 percentage points from Baseline and to a value &lt;50%. The percentage of participants with at least one secondary cardiac endpoint event was reported, excluding those with both a primary and secondary cardiac endpoint event. The 95% CI was calculated by the Pearson-Clopper method for a one-sample binomial.</description>
        <time_frame>From Baseline until time of event (maximum up to 10 years)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Observation Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin was provided.</description>
          </group>
          <group group_id="O2">
            <title>Herceptin 1-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
          <group group_id="O3">
            <title>Herceptin 2-Year Arm</title>
            <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Secondary Cardiac Endpoint Events Compared to Observation: 10-Year Maximum Follow-Up</title>
          <description>Secondary cardiac endpoint events included NYHA Class I or II CHF with a drop in LVEF measured by multiple-gated acquisition or electrocardiogram, unless the subsequent assessment of LVEF indicated a return to levels that did not meet the definition of a significant LVEF drop. A significant LVEF drop was defined as an absolute reduction of at least 10 percentage points from Baseline and to a value &lt;50%. The percentage of participants with at least one secondary cardiac endpoint event was reported, excluding those with both a primary and secondary cardiac endpoint event. The 95% CI was calculated by the Pearson-Clopper method for a one-sample binomial.</description>
          <population>Safety Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1744"/>
                <count group_id="O2" value="1682"/>
                <count group_id="O3" value="1673"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86" lower_limit="0.48" upper_limit="1.41"/>
                    <measurement group_id="O2" value="4.40" lower_limit="3.47" upper_limit="5.49"/>
                    <measurement group_id="O3" value="7.29" lower_limit="6.09" upper_limit="8.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From Baseline until end of treatment (maximum up to 2 years) with the exception of cardiac/cardiovascular events, second primary malignancies, pregnancies, and Herceptin-related adverse events (maximum up to 10 years)</time_frame>
      <desc>Analysis Population Description: Safety Population</desc>
      <group_list>
        <group group_id="E1">
          <title>Observation Arm</title>
          <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin was provided. After the release of initial study results, participants in the Observation Arm were allowed to cross over to receive adjuvant Herceptin prior to disease recurrence. As such, adverse events that occurred after crossover were not included in the safety analyses for this arm.</description>
        </group>
        <group group_id="E2">
          <title>Herceptin 1-Year Arm</title>
          <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
        </group>
        <group group_id="E3">
          <title>Herceptin 2-Year Arm</title>
          <description>Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="143" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="269" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="344" subjects_at_risk="1673"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Pericarditis lupus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Dermoid cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Odontogenic cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Tooth hypoplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Ventricular septal defect</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Otosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Basedowâ€™s disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1673"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Eyelid ptosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1673"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Axillary pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Breast complication associated with device</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Device breakage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Device leakage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Fat necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Granuloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Ill-defined disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Medical device pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Mucosal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Multi-organ disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Bartholinâ€™s abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Breast cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Catheter site cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Device related sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Endometritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Extradural abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Genital infection female</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Lymphangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Mastitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Muscle abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Pulmonary mycosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Salpingo-oophoritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Spinal cord abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Fractured coccyx</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Nerve injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Post-traumatic neck syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Postoperative hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Pulmonary contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Radiation pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Scar</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Spinal column injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Wound secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Tendon disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma pancreas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Adenoid cystic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Adenoma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Adenosquamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Angiosarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Benign breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Benign neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Benign ovarian tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Bladder papilloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Breast cancer in situ</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Carcinoid tumour of the gastrointestinal tract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma stage 0</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma stage II</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Colorectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Endometrial adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Fibroadenoma of breast</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Gastric adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stromal tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Hodgkinâ€™s disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Infected neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Inflammatory myofibroblastic tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Invasive papillary breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Lipofibroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Mantle cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Metastatic renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Oesophageal squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Ovarian adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Pagetâ€™s disease of nipple</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Retro-orbital neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Second primary malignancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the vulva</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Undifferentiated sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Uterine leiomyosarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Vulval cancer stage 0</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Central nervous system haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Cerebellar atrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimerâ€™s type</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Nystagmus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Optic neuritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Paresis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion missed</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Complication of pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Delivery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="1673"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Delusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adnexa uteri mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Breast calcifications</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Breast disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Breast dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Breast fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Breast haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Breast hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Breast inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Breast necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Cervical polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Fibrocystic breast disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Genital prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Nipple exudate bloody</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Throat tightness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Vocal cord polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Prurigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Scar pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Skin mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Telangiectasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Toxic skin eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Mammoplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Nerve block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Jugular vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Microangiopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Subclavian vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Vena cava thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1673"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1076" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="1389" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="1440" subjects_at_risk="1673"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="127" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="84" subjects_at_risk="1673"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="155" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="180" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="134" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="157" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="99" subjects_at_risk="1673"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="102" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="119" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="84" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="99" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="128" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="198" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="246" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="101" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="116" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="145" subjects_at_risk="1673"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="142" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="187" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="269" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="84" subjects_at_risk="1673"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="152" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="225" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="246" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="106" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="146" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="137" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="91" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="92" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="104" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="107" subjects_at_risk="1673"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="89" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="201" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="250" subjects_at_risk="1673"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="80" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="96" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="75" subjects_at_risk="1673"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="116" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="147" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="116" subjects_at_risk="1673"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="83" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Onychoclasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="98" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="99" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="135" subjects_at_risk="1673"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="130" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="166" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="159" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="104" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="128" subjects_at_risk="1673"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="1744"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="1682"/>
                <counts group_id="E3" subjects_affected="92" subjects_at_risk="1673"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-La Roche</organization>
      <phone>800-821-8590</phone>
      <email>global-roche-genentech-trials@gene.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

